[1] |
Protease Inhibitors (HIV) 2012; [PubMed PMID: 31644200] |
[2] |
Su CT,Ling WL,Lua WH,Haw YX,Gan SK, Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance. BMC bioinformatics. 2016 Dec 22; [PubMed PMID: 28155724] |
[3] |
Izzedine H,Lescure FX,Bonnet F, HIV medication-based urolithiasis. Clinical kidney journal. 2014 Apr; [PubMed PMID: 25852859] |
[4] |
Lee A,Saito E,Ekins S,McMurtray A, Extracellular binding of indinavir to matrix metalloproteinase-2 and the alpha-7-nicotinic acetylcholine receptor: implications for use in cancer treatment. Heliyon. 2019 Sep; [PubMed PMID: 31687607] |
[5] |
Sharma S,Baksi R,Agarwal M, Repositioning of anti-viral drugs as therapy for cervical cancer. Pharmacological reports : PR. 2016 Oct; [PubMed PMID: 27379616] |
[6] |
Calitz C,Gouws C,Viljoen J,Steenekamp J,Wiesner L,Abay E,Hamman J, Herb-Drug Pharmacokinetic Interactions: Transport and Metabolism of Indinavir in the Presence of Selected Herbal Products. Molecules (Basel, Switzerland). 2015 Dec 10; [PubMed PMID: 26690396] |
[7] |
Nicolussi S,Drewe J,Butterweck V,Meyer Zu Schwabedissen HE, Clinical relevance of St. John's wort drug interactions revisited. British journal of pharmacology. 2019 Nov 19; [PubMed PMID: 31742659] |
[8] |
Matłosz B,Pietraszkiewicz E,Firląg-Burkacka E,Grycner E,Horban A,Kowalska JD, Risk factors for kidney disease among HIV-1 positive persons in the methadone program. Clinical and experimental nephrology. 2019 Mar; [PubMed PMID: 30218298] |
[9] |
Gupta V,El Ters M,Kashani K,Leung N,Nasr SH, Crystalglobulin-induced nephropathy. Journal of the American Society of Nephrology : JASN. 2015 Mar; [PubMed PMID: 25190731] |
[10] |
Loens C,Amet S,Isnard-Bagnis C,Deray G,Tourret J, [Nephrotoxicity of antiretrovirals other than tenofovir]. Nephrologie [PubMed PMID: 29500080] |
[11] |
Aarnoutse RE,Wasmuth JC,Fätkenheuer G,Schneider K,Schmitz K,de Boo TM,Reiss P,Hekster YA,Burger DM,Rockstroh JK, Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir. Antiviral therapy. 2003 Aug; [PubMed PMID: 14518700] |
[12] |
Gulick RM,Mellors JW,Havlir D,Eron JJ,Gonzalez C,McMahon D,Richman DD,Valentine FT,Jonas L,Meibohm A,Emini EA,Chodakewitz JA, Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. The New England journal of medicine. 1997 Sep 11; [PubMed PMID: 9287228] |
[13] |
Plosker GL,Noble S, Indinavir: a review of its use in the management of HIV infection. Drugs. 1999 Dec; [PubMed PMID: 10651394] |
[14] |
Fogo AB,Lusco MA,Najafian B,Alpers CE, AJKD Atlas of Renal Pathology: Indinavir Nephrotoxicity. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017 Jan; [PubMed PMID: 28007196] |
[15] |
Hortin GL,King C,Miller KD,Kopp JB, Detection of indinavir crystals in urine: dependence on method of analysis. Archives of pathology [PubMed PMID: 10656734] |
[16] |
Lehman HP,Benson JO,Beninger PR,Anderson CA,Blumenthal SJ,Sharrar RG, A five-year evaluation of reports of overdose with indinavir sulfate. Pharmacoepidemiology and drug safety. 2003 Sep; [PubMed PMID: 14513658] |
[17] |
Burkhart KK,Kemerer K,Donovan JW, Indinavir overdose. Journal of toxicology. Clinical toxicology. 1998; [PubMed PMID: 9865247] |